|
Market Closed -
Nasdaq
04:00:00 2026-11-02 pm EST
|
5-day change | 1st Jan Change | ||
| 170.33 USD | -0.21% |
|
+7.34% | +38.77% |
| Nov. 02 | Dr Reddy's gets tentative US FDA nod for generic HIV prevention | RE |
| Oct. 30 | Gilead's HIV Franchise Supports Growth Outlook, RBC Says | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 211B | - | ||||
| 1,257B | |||||
| 651B | |||||
| 510B | |||||
| 388B | |||||
| 366B |
- Stock Market
- Stocks
- GILD Stock
- Charts Gilead Sciences, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
